Skip to main content

Table 1 Subject characteristics.

From: Differences in Regional Brain Activation Patterns Assessed by Functional Magnetic Resonance Imaging in Patients with Systemic Lupus Erythematosus Stratified by Disease Duration

 

ST (n = 6) (disease duration <2 years)

LT (n = 7) (disease duration >10 years)

P

Disease duration (years)

0.79 ± 0.49

15.29 ± 5.53

0.003a

Age

   

Mean

25.7 ± 2.66

43.1 ± 9.16

0.008a

Median

25.5

45

 

Range

23–29

27–55

 

Sex

   

Female (%)

83

100

 

Male (%)

17

0

 

Ethnicity

   

African American (%)

17

57

0.242

Hispanic (%)

83

29

0.103

Caucasian (%)

0

14

0.462

Education (years)

12.83 ± 2.14

12.85 ± 3.02

0.942

SLEDAI

1.67 ± 1.5

2.0 ± 2.30

0.940

DI

0.17 ± 0.41

1.29 ± 1.25

0.048a

History of NPSLE

0

0

 

Anti-dsDNA titer (%)b

33

43

0.59

Anticardiolipin (%)c

33

29

0.72

Prednisoned

14.17 ± 14.71

4.11 ± 5.62

0.127

Cellcept(current)

67%

14%

0.063

Azathioprine(current)

0

14%

0.355

Cyclophosphamide(current)

17%

0

0.280

Current DMARDe

83%

29%

0.058

DMARD ever

83%

71%

0.626

Hypertensionf

50%

0

0.181

Diabetes mellitusg

0

14%

0.355

  1. aP< 0.05.
  2. bCurrent anti-dsDNA titer; percent positive.
  3. cAnticardiolipin antibody titer; percent positive IgG or IgM by history
  4. dCurrent prednisone dose.
  5. eDMARD, disease-modifying antirheumatic drugs include cyclophosphamide, methotrexate, azathioprine or cellcept for >2 months.
  6. fCurrent hypertension requiring medication.
  7. gCurrent diabetes mellitus requiring medication.